Abstract: The present formulation is an analgesic, anesthetic and anti-pruritic formulation with from about 10.0 wt % to about 75.0 wt % Emu oil; from about 10.0 wt % to about 33.0 wt % benzyl alcohol; from about 0.25 wt % to about 5.0 wt % allantoin; from about 0.1 wt % to about 5.0 wt % methylparaben; from about 0.1 wt % to about 2.0 wt % propylparaben; and from about 0.5 wt % to about 4.0 wt % of lidocaine, wherein the formulation is adapted to inhibit microbial activity from Escherichia coli, Salmonella typhimurium, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus faecalis, Bacillus cereus, Candida albicans, Streptococcus agalactiae or combinations thereof, and wherein the lidocaine relieves pain on the epidermis of humans and animals of skin irritations, wounds, or burns.

Abstract: Improved aerodynamically light particles for delivery to the pulmonary system, and methods for their preparation and administration are provided. In a preferred embodiment, the aerodynamically light particles are made of a biodegradable material and have a tap density less than 0.4 g/cm3 and a mass mean diameter between 5 ?m and 30 ?m. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of a functionalized polyester graft copolymer consisting of a linear ?-hydroxy-acid polyester backbone having at least one amino acid group incorporated herein and at least on poly(amino acid) side chain extending from an amino acid group in the polyester backbone. In one embodiment, aerodynamically light particles having a large mean diameter, for example greater than 5 ?m, can be used for enhanced delivery of a therapeutic or diagnostic agent to the alveolar region of the lung.

Abstract: An antifungal fragrance composition containing as its active ingredients: (a) at least one type of fragrance component selected from the group consisting of an aliphatic or aromatic aldehyde having 5 to 16 carbon atoms and an aliphatic or aromatic alcohol having 5 to 16 carbon atoms, and (b) at least one type of compound different from component (a) and selected from the group consisting of an aliphatic or aromatic aldehyde, an aliphatic or aromatic alcohol, acetal and ester that produces synergistic antifungal effects in the presence of said fragrance component (a). The present antifungal fragrance composition demonstrates antifungal activity by adding a small amount of oils and fragrant chemical products that have a minimal effect on the scent of the fragrance composition.

Abstract: A pharmaceutical composition for topical administration, including, as the pharmaceutically active component, at least 5% by weight, based on the total weight of the composition of a piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof; an acid in an amount to completely solubilise the piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof; a solvent composition including at least two of water, a lower alcohol and a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols; wherein when the co-solvent includes propylene glycol, it is present in an amount of less than approximately 10% by weight.

Abstract: A method of treating pulmonary hypoplasia in infants has been developed, wherein epidermal growth factor (EGF) is administered to the pulmonary system of an infant in need of treatment thereof. The EGF is administered as an aerosol or dry powder directly to the pulmonary tree, or into the amniotic fluid before birth if a situation such as oligohydramnios is recognized pre-term. The method can also be used to treat persistent pulmonary hypertension of the newborn. A hydrophobic angiotensin I-converting enzyme (ACE) inhibitor such as ramipril can also be used for the oral treatment of persistent pulmonary hypertension of the newborn.

Abstract: A fusogenic liposome composition for delivering a liposome-entrapped compound into the cytoplasm of a target cell is described. The liposomes have an outer surface coating of chemically releasable hydrophilic polymer chains which shield hydrophobic polymers on the liposome outer surface. Release of the hydrophilic polymer chains exposes the hydrophobic polymers for interaction with outer cell membranes of the target cells to promote fusion of the liposome with the target cells. Also disclosed is a method for using the composition to deliver a compound to target cells, and a method for selecting suitable hydrophobic polymers for use in the composition.

Abstract: A cosmetic composition comprising at least one water-soluble or water-dispersible polymer which comprises, in copolymerized form, a) at least one ?,?-ethylenically unsaturated monomer of the formula I in which R1 is hydrogen or C1-C8-alkyl, and X1 is O or NR2, where R2 is hydrogen, C1-C8-alkyl or if C5-C8-cycloalkyl, b) at least one ?,?-ethylenically unsaturated mono- and/or dicarboxylic acid, c) at least one compound having at least one ?,?-ethylenically unsaturated double bond and at least 5 alkylene oxide units per molecule, d) at least one compound having at least one ?,?-ethylenically unsaturated double bond and at least one straight-chain or branched C8-C30-alkyl or -alkylene radical per molecule, where the components c) and/or d) can be partially or completely replaced by a component e), where e) is at least one compound having at least one ?,?-ethylenically unsaturated double bond, at least 5 alkylene oxide units and at least one straight-chain or branched C8-C30-alkyl or -alkylene radical pe

Abstract: The present invention provides an apparatus and method for controlled release of a fumigant into a wooden structure to prevent decay of that structure. According to the present invention, a fumigant in an ampule or container is inserted into the wooden structure. The ampule or container is made of a polymeric material that does not react with the fumigant, but having walls which are permeable to the fumigant such that, when inserted into the wooden structure, the rate of release of the fumigant through the walls of the ampule is slow enough to continuously treat and arrest decay of the wooden structure, particularly decay caused by fungi, over extended periods of time (i.e., 1, 5, 7, 10, 15, 20 or 30 years). The rate of release of the fumigant can be controlled by the type of fumigant, the shape of the container, the specific polymer used to make the container, and by the thickness of the container wall.

Abstract: Disclosed is a compound of one of the formulae wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 each, independently of the others, is an alkyl group, an aryl group, an arylalkyl group, or an alkylaryl group, R11 and R12 each, independently of the others, is an alkylene group, an arylene group, an arylalkylene group, or an alkylarylene group, G is a cationic moiety, A is an anionic moiety, n is an integer representing the number of repeat —OSi(R7)(R8)— monomer units, a is an integer representing the number of repeat —OSi(R10)(R12-lightfastness moiety)— monomer units, and c is an integer representing the number of repeat —OSi(R9)(R11-hydrophilic moiety)— monomer units.

Abstract: The present invention relates to the delivery of analgesics through an inhalation route. Specifically, it relates to aerosols containing acetaminophen, orphenadrine or tramadol that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of acetaminophen, orphenadrine or tramadol. In a method aspect of the present invention, one of acetaminophen, orphenadrine or tramadol is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of acetaminophen, orphenadrine or tramadol, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal.

Abstract: Spray dried particles having specified aerodynamic characteristics are produced by atomizing a liquid feed and contacting the liquid feed with a drying gas, such as, for example, air or nitrogen. The humidity of the drying gas is controlled to a value, expressed, for instance, as dew point, which is known to produce particles having a specified tap density or aerodynamic diameter. Particles having a volume median geometric diameter greater than about 5 microns and a tap density less than about 0.4 g/cm3 are preferred.

Abstract: The present invention provides highly dispersible spray-dried powder compositions, and in particular, inhaleable dry powder compositions for aerosolized delivery to the lungs. The powders of the invention are produced by spray drying a 4 ?-helix bundle protein under conditions which both (i) protect the protein from aggregation and (ii) provide particles suitable for inhalation (i.e., demonstrating superior aerosol performance).

Abstract: Stable aqueous formulations which are free of products derived from human or animal origin and which maintain high biological activity and high chemical and physical stability of alpha-type interferon for an extended period of time. Methods of producing stable aerosol formulations of the same for delivery to the lungs are also provided, as well as systems and methods of delivering the formulations to the lungs for systemic absorption.

Abstract: Disclosed is a combination product for use in treating asthma and other respiratory conditions comprising a medicament comprising a surface active phospholipid composition in the form of a fine powder and an antiasthma drug. The product is arranged to be administered to the lungs by inhalation, for example, by the disclosed devices.

Abstract: An aqueous stable foam, suitable for use as a vaginal or hemorrhoidal wipe agent, containing at least one surfactant and at least one foam stabilizing agent can be dispensed to bathroom tissue or the like for application to the vaginal or anal area.

Abstract: The present invention relates to the delivery of compounds for the treatment of Parkinsons through an inhalation route. Specifically, it relates to aerosols containing antiparkinsonian drugs that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of an antiparkinsonian drug. In a method aspect of the present invention, an antiparkinsonian drug is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of an antiparkinsonian drug to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal.

Abstract: A tablet that includes stevia, water soluble binder, water soluble lubricant, active agent, and effervescent agent.

Abstract: A topical composition containing an aqueous gel which contains a hydrophilic gelling material, wherein the gel has at least one of the following properties: an initial viscosity V0 ranging from 3000 to 50,000 Pa.s, wherein the initial viscosity is stable up to a shear strain C1, a viscosity V2 after shear at a strain C2, wherein a ratio of V0/V2 is greater than or equal to 1000, and a difference of C2-C1 is less than or equal to 100 Pa.

Abstract: The present invention relates to the delivery of erectile dysfunction drugs through an inhalation route. Specifically, it relates to aerosols containing erectile dysfunction drugs that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of an erectile dysfunction drug. In a method aspect of the present invention, an erectile dysfunction drug is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of an erectile dysfunction drug, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal.

Abstract: Esters of L-carnitine and alkanoyl L-carnitines are described which can be used as cationic lipids for the intracellular delivery of pharmacologically active compounds. New esters of L-carnitine and alkanoyl L-carnitines of formula (I) are also disclosed wherein the R groups are as defined in the description.

Abstract: The present invention relates to the delivery of antidepressants through an inhalation route. Specifically, it relates to aerosols containing an antidepressant that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of an antidepressant. In a method aspect of the present invention, an antidepressant is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of an antidepressant to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal.

Abstract: The subject invention is directed to the treatment of respiratory disorders by intratracheal administration of an effective amount of lysozyme. Respiratory disorders include emphysema, pneumonia, respiratory distress syndrome, bronchopulmonary dysplasia, interstitial fibrosis, cystic fibrosis, and neoplasia. The treatment is intended for a variety of animals, such as premature neonates to adult humans. Administration of lysozyme may be performed by aerosol, which can be generated by a nebulizer or by instillation. The lysozyme may be administered alone or with a carrier such as saline solution, DMSO, and alcohol, or water. It may also be used as a vehicle for the intratracheal administration of drugs or other agents to the lung. The lysozyme may be isolated from a natural source, such as eggs, or synthesized by a bioprocess, such as fermentation. The effective daily amount of lysozyme is from about 10 &mgr;g/kg to about 1 mg/kg of body weight.

Abstract: A method of producing a porous, liquid absorbent, open-cell polymeric foam material having properties which makes it suitable for use as an absorbent structure in absorbent articles such as diapers, pant diapers, sanitary napkins, incontinence guards, wound dressings, bed protections etc, comprising dissolving a polymer in a solvent, adding a surfactant and causing foaming, after which the polymer is crosslinked in the foamed mixture by means of a crosslinking agent. The temperature of the foam thus formed is lowered to a temperature below the freezing point of the solvent and the crosslinking reaction is continued during the freezing step, and after the main part of the solvent is removed from the formed foam material.

Abstract: The present invention is directed to a method for the treatment of gastroparesis by the use of metoclopramide nasal formulation.

Abstract: A sprayable analgesic composition containing an analgesic which is absorbed into the bloodstream through the buccal mucosa and a pharmacologically acceptable liquid carrier.

Abstract: Provided is a compressed anti-solvent technique for manufacture of insulin-containing powders for pulmonary delivery. The insulin is processed in a cosolvent system including two or more mutually soluble organic solvents. Also provided are powders manufacturable by the manufacture method, including powders of substantially pure insulin and powders including a biocompatible polymer for pulmonary sustained insulin release applications. Also provided are packaged products including insulin-containing powder in a container that is receivable by and operable with a dry powder inhaler to produce an aerosol including dispersed insulin-containing particles when the inhaler is actuated.

Abstract: The present invention relates to pharmaceutical compositions and methods for improved solubilization of triglycerides and improved delivery of therapeutic agents. Compositions of the present invention include a carrier, where the carrier is formed from a combination of a triglyceride and at least two surfactants, at least one of which is hydrophilic. Upon dilution with an aqueous medium, the carrier forms a clear, aqueous dispersion of the triglyceride and surfactants.

Abstract: A storage and delivery system for directly applying nitric oxide to a user includes a portable and disposable capsule and a source of nitric oxide gas disposed within the cavity. Gas flow control apparatus controls the flow of nitric oxide gas from the cavity. Gas flow initiation apparatus allows the user to initiate the flow of nitric oxide gas. The encapsulated nitric oxide gas is applied by positioning the capsule proximate to the objective site of the user and initiating flow of the nitric oxide gas.

Abstract: A formulation of delta-9-tetrahydrocannabinol in a semi-aqueous solvent, such as 35:10:55 alcohol:water:propylene glycol (v/v), produces a stable clear solution near the solubility point of the drug. Because delta-9-tetrahydrocannabinol has poor affinity for the formulation, it is able to partition out and transport across cell membranes to reach the bloodstream quickly. This has been demonstrated by the comparative tmax values achieved in single dose intravenous and 14 day multiple dose inhalation studies conducted in dogs and rats.

Abstract: Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.

Abstract: The present invention relates to the delivery of a migraine headache drug through an inhalation route. Specifically, it relates to aerosols containing a migraine headache drug that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of a migraine headache drug. In a method aspect of the present invention, a migraine headache drug is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of a migraine headache drug, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal.

Abstract: The present invention relates to the delivery of antihistamines through an inhalation route. Specifically, it relates to aerosols containing antihistamines that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of an antihistamine. In a method aspect of the present invention, an antihistamine is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of an antihistamine, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal.

Abstract: The present invention relates to the delivery of beta-blockers through an inhalation route. Specifically, it relates to aerosols containing atenolol, pindolol, esmolol, propranolol, or metoprolol that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of atenolol, pindolol, esmolol, propranolol, or metoprolol. In a method aspect of the present invention, one of atenolol, pindolol, esmolol, propranolol, or metoprolol is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of atenolol, pindolol, esmolol, propranolol, or metoprolol, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal.

Abstract: Systemic delivery of insulin to a mammalian host is accomplished by inhalation of a dry powder of insulin. It has been found that dry insulin powders are rapidly absorbed through the alveolar regions of the lungs.

Abstract: The present invention relates to the delivery of drug esters through an inhalation route. Specifically, it relates to aerosols containing drug esters that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of drug ester. In a method aspect of the present invention, a drug ester is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of drug ester, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal.

Abstract: There are provided according to the invention compounds of the formula (I) or a salt or solvate thereof, wherein: n represents an integer 1 to 6; N represents an integer 1 to 15; R1 represents (CO)xC1-9alkyl or (CO)xC1-9fluoroalkyl, which fluoroalkyl moiety contains at least 1 fluorine atom and not more than 3 consecutive perfluorocarbon atoms wherein x represents 0 or 1; and R2 and R3 independently represent C1-3alkyl or hydrogen. There are also provided pharmaceutical aerosol formulations employing said compounds as suspension stabilising agents.

Abstract: The present invention relates to the delivery of sedative-hypnotics through an inhalation route. Specifically, it relates to aerosols containing sedative-hypnotics that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of a sedative-hypnotic. In a method aspect of the present invention, a sedative-hypnotic is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of a sedative-hypnotic, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal.

Abstract: The present invention relates to the delivery of nonsteroidal antiinflammatory drugs (NSAIDs) through an inhalation route. Specifically, it relates to aerosols containing NSAIDs that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of an NSAID. In a method aspect of the present invention, an NSAID is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of an NSAID, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal.

Abstract: A pharmaceutical composition for the administration of phloroglucinol includes phloroglucinol in combination with a buffer system capable of buffering the composition when placed in an aqueous medium to a pH between 3 and 7.

Abstract: In a solution composition for use in an aerosol inhaler which comprises an active material, a propellant containing a hydrofluoroalkane, a cosolvent and optionally a low volatility compound the use of a mixture of HFA 134a and HFA 227 allows to modulate the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler to target specific regions of the respiratory tract. Moreover the fine particle dose (FPD) of the active ingredient in the composition increases by reducing the metering chamber volume.

Abstract: Liquid pharmaceutical compositions comprising at least one thyroid hormone, ethanol, a pH adjusting agent, and water are disclosed. The compositions may be delivered by a metered dosage delivery system such as an aerosol or pump-action spray, and are useful in the treatment of disorders associated with an impairment of thyroid hormone function in animals including human beings.

Abstract: The present invention provides an apparatus and method for controlled release of a fumigant into a wooden structure to prevent decay of that structure. According to the present invention, a fumigant in an ampule or container is inserted into the wooden structure. The ampule or container is made of a polymeric material that does not react with the fumigant, but having walls which are permeable to the fumigant such that, when inserted into the wooden structure, the rate of release of the fumigant through the walls of the ampule is slow enough to continuously treat and arrest decay of the wooden structure, particularly decay caused by fungi, over extended periods of time (i.e., 1, 5, 7, 10, 15, 20 or 30 years). The rate of release of the fumigant can be controlled by the type of fumigant, the shape of the container, the specific polymer used to make the container, and by the thickness of the container wall.

Abstract: Powder compositions usable to reduce malodours, and powder formulations from which can be made aqueous spray compositions usable to reduce malodours, each comprise, as a major ingredient, amphoteric material, for example sodium bicarbonate, potassium bicarbonate, or zinc oxide, together with one or more minor ingredients, in particular a drying agent, for example sodium sulphate. Other minor ingredients may be an ammonia-odour/sulphide-odour remover, for example ferrous sulphate or zinc sulphate, and an adsorbent, for example zeolite, in the case of a powder formulation; or a filler, for example potassium chloride, or an organic complexing agent, for example cyclodextrin, or a surfactant, in the case of a stock formulation.

Abstract: A carbon dioxide-containing viscous composition wherein carbon dioxide bubbles are retained in an aqueous viscous composition. Use of the composition makes it possible to treat or ameliorate itching accompanying mucocutaneous diseases or mucocutaneous disorders, mucocutaneous injury, dental diseases, skin ulcer, cryesthesia and numbness caused by peripheral circulatory disorders, musculoskeletal diseases, nervous system diseases, keratosis, constipation, unwanted hair re-growing after depilation, cosmetic troubles in the skin or hair, partial obesity, etc. while exerting little side effects.

Abstract: Systemic delivery of insulin to a mammalian host is accomplished by inhalation of a dry powder of insulin. It has been found that dry insulin powders are rapidly absorbed through the alveolar regions of the lungs.

Abstract: A method of conditioning and oxidatively dyeing human hair includes applying an oxidative hair dyeing composition to the human hair in order to dye the human hair and, simultaneously or subsequently to the applying of the oxidative hair dyeing composition, applying a particular hair conditioning composition to the hair. This hair conditioning composition has a pH value of from 3.4 to 3.9, which corresponds to an isoelectric point of the human hair, and contains from 0.001 to 2.5% by weight of a cationic polymer, an optional pH buffer and preferably additional conditioning ingredients, such as a cationic surfactant and/or a fatty alcohol.

Abstract: The present invention is directed to a self-foaming shaving composition in the form of a lotion. The shaving composition comprises water, a water dispersible surface active agent capable of forming a lather, a volatile self-foaming agent, and a water soluble thickening agent wherein the composition is in the form of a self-foaming lotion having an elastic modulus (G′) of about 100 to about 1000 Pascals, preferably about 200 to about 900 Pa, most preferably about 400 to about 800 Pa (measured with a rheometer at frequency 1 Hz, oscillatory stress range 0.01-1.0 Pa, temperature 5° C., Gap 1000 &mgr;m). The present invention is also directed to an improved shaving method in which a shaving composition of the present invention is applied to an area of skin, then said area is shaved, preferably with a wet razor.

Abstract: Provided is a compressed anti-solvent technique for manufacture of drug-containing powders for pulmonary delivery. The drug is processed in a cosolvent system including two or more mutually soluble organic solvents. Also provided are powders manufacturable by the manufacture method, including powders of substantially pure drug and powders including a biocompatible polymer for pulmonary sustained drug release applications. Also provided are packaged products including drug-containing powder in a container that is receivable by and operable with a dry powder inhaler to produce an aerosol including dispersed drug-containing particles when the inhaler is actuated.

Abstract: Composition and methods for improving air quality, disinfecting surfaces, and prevention of a respiratory infection. The method can decrease pathogen and/or parasitic concentrations in closed rooms and surfaces by the application of an antiseptic composition. The composition can be a pressurized or foaming solution containing a single terpene, a terpene mixture, and/or a liposome:terpene(s) combination with or without surfactant. The composition can be a true solution of an effective amount of an effective terpene and a carrier such as water. The composition can be a suspension or emulsion of terpene, surfactant, and carrier. Application can be, for example, by spraying a confined space with a solution of the present invention.

Abstract: The use of specific perfume ingredients, e.g. tricyclodecenyl allyl ether, to repel insects. The perfume ingredients may be used in a composition comprising from 0.1 to 40 percent by weight of one or more of the perfume ingredients. Preferably at least one of the perfume ingredients has a hydrophobicity such that the common logarithm of the octanol-water partition coefficient, log P, of the perfume ingredient is in the range 1.0 to 6.0.